EQS-Adhoc

Relief Therapeutics Announces Executive Changes

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Personnel Relief Therapeutics Announces Executive Changes 30-Nov-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Executive Changes

• Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD
• Jeremy Meinen promoted to Chief Accounting Officer
• Marco Marotta promoted to Chief Business Officer

Geneva, Switzerland, November 30, 2021 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced today a series of executive changes.

Nermeen Varawalla, MD, PhD, MBA has been appointed to the position of Chief Medical Officer, reporting to Raghuram (Ram) Selvaraju, PhD, MBA, Chairman of Relief. Dr. Varawalla will replace Gilles Della Corte, MD, who is leaving to pursue other opportunities. Nermeen brings to Relief deep expertise in clinical trials and medical affairs, having successfully led numerous international teams and clinical development programs for the global adoption of new pharmaceuticals and medical devices.

"Nermeen's more than 30 years of international experience in the pharmaceutical sector, including her proven clinical development and regulatory expertise and experience within the rare disease space, is a major asset which we will immediately leverage as we seek to expand our clinical pipeline through our recently announced strategic collaboration with InveniAI, and as we progress our current proprietary and partnered product development programs," stated Dr. Selvaraju. "Her contributions will be invaluable across the board including, of course, as it relates to the potential of RLF-100(TM) (for, among other respiratory issues, complications of COVID-19), the prospective launch of ACER-001 to treat Urea Cycle Disorders in 2022, and our other pipeline programs."